Research Focus

Former Employee. Medicine; Research Project Mgr

Recent additions – View all

1. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

   Meeting Abstract

   Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
   Journal of Clinical Oncology (2014)

   Fulltext@MSK | Save
2. Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

   Meeting Abstract

   Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
   Annals of Oncology (2014)

   Fulltext@MSK | Save
3. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-programmed death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

   Meeting Abstract

   Sznol, M.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Gordon, R.; Seal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
   Asia-Pacific Journal of Clinical Oncology (2014)

   Fulltext@MSK | Save